1. Luo, Maowu, Bao, Lei, Xue, Yuanyuan, Wang, Yingfei, Luo, Weibo. 2024. ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2. In The Journal of clinical investigation, 134, . doi:10.1172/JCI171166. https://pubmed.ncbi.nlm.nih.gov/38488001/
2. Jia, Pan, Li, Xiang, Wang, Xuelei, Qin, Jun, Lu, Wei. 2021. ZMYND8 mediated liquid condensates spatiotemporally decommission the latent super-enhancers during macrophage polarization. In Nature communications, 12, 6535. doi:10.1038/s41467-021-26864-x. https://pubmed.ncbi.nlm.nih.gov/34764296/
3. Cao, Zhendong, Budinich, Krista A, Huang, Hua, Berger, Shelley L, Shi, Junwei. 2021. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. In Molecular cell, 81, 3604-3622.e10. doi:10.1016/j.molcel.2021.07.018. https://pubmed.ncbi.nlm.nih.gov/34358447/
4. Adhikary, Santanu, Singh, Vipin, Choudhari, Ramesh, Gadad, Shrikanth S, Das, Chandrima. 2022. ZMYND8 suppresses MAPT213 LncRNA transcription to promote neuronal differentiation. In Cell death & disease, 13, 766. doi:10.1038/s41419-022-05212-x. https://pubmed.ncbi.nlm.nih.gov/36064715/
5. Pan, Qiang, Zhong, Shanshan, Wang, Hanling, Xiao, Yichuan, Qin, Jun. 2021. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. In Molecular cell, 81, 2736-2751.e8. doi:10.1016/j.molcel.2021.04.009. https://pubmed.ncbi.nlm.nih.gov/33932349/
6. Li, Na, Li, Yuanyuan, Lv, Jie, Li, Haitao, Lee, Min Gyu. 2016. ZMYND8 Reads the Dual Histone Mark H3K4me1-H3K14ac to Antagonize the Expression of Metastasis-Linked Genes. In Molecular cell, 63, 470-84. doi:10.1016/j.molcel.2016.06.035. https://pubmed.ncbi.nlm.nih.gov/27477906/
7. Dias, Kerith-Rae, Carlston, Colleen M, Blok, Laura E R, Harvey, Robert J, Roscioli, Tony. 2022. De Novo ZMYND8 variants result in an autosomal dominant neurodevelopmental disorder with cardiac malformations. In Genetics in medicine : official journal of the American College of Medical Genetics, 24, 1952-1966. doi:10.1016/j.gim.2022.06.001. https://pubmed.ncbi.nlm.nih.gov/35916866/
8. Dou, Changwei, Mo, Huanye, Chen, Tianxiang, Guo, Cheng, Zhang, Chengwu. 2021. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis. In Pathology, research and practice, 219, 153345. doi:10.1016/j.prp.2021.153345. https://pubmed.ncbi.nlm.nih.gov/33517164/
9. Choi, Sangjoon, Lee, Keun-Woo, Koh, Hyun Hee, Park, Cheol-Keun, Ha, Sang Yun. 2021. Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma. In Journal of cancer research and clinical oncology, 147, 3517-3534. doi:10.1007/s00432-021-03768-3. https://pubmed.ncbi.nlm.nih.gov/34462784/
10. Carney, Stephen V, Banerjee, Kaushik, Mujeeb, Anzar, Lowenstein, Pedro R, Castro, Maria G. . Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance. In Clinical cancer research : an official journal of the American Association for Cancer Research, 29, 1763-1782. doi:10.1158/1078-0432.CCR-22-1896. https://pubmed.ncbi.nlm.nih.gov/36692427/